Treats plaque psoriasis. ANDA 206441, held by Padagis Israel. Desoximetasone.
As of Nov 15, 2026, ANDA 206441 (Desoximetasone), held by Padagis Israel, was first approved by FDA on Jan 20, 2017, with 1 approved supplement and 0 published complete response letters.
Desoximetasone topical spray is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 20, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desoximetasone0.25% · spray;topical | Desoximetasone | Rx |
| Aug 23, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 20, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
